The Global Culinary Tourism Market has witnessed continuous growth in the last few years and is projected to grow even further during the forecast period of 2024-2033. The assessment provides a 360° view and insights - outlining the key outcomes of the Culinary Tourism market, current scenario analysis that highlights slowdown aims to provide unique strategies and solutions following and benchmarking key players strategies. In addition, the study helps with competition insights of emerging players in understanding the companies more precisely to make better informed decisions.

Browse for Full Report at @ https://www.thebrainyinsights.com/report/culinary-tourism-market-14100

Recent Developments

• New biologic approvals/labels

  • Lebrikizumab (Ebglyss, Eli Lilly): FDA approval for moderate-to-severe AD in adults (Oct 2024). EU approvals rolled out across 2024–2025. 

  • Nemolizumab (Nemluvio, Galderma): FDA approved (Dec 2024) for moderate-to-severe AD (12+ yrs) in combination with topicals; also approved earlier for prurigo nodularis.

  • Upadacitinib (Rinvoq, AbbVie) & Abrocitinib (Cibinqo, Pfizer): U.S. AD approvals maintained with boxed warnings; active global rollouts/label updates continue. 

  • Tralokinumab (Adbry/Adtralza, LEO Pharma): U.S./EU AD approvals (2021) with ongoing lifecycle updates (e.g., autoinjector; regional launches).

  • Ruxolitinib cream (Opzelura, Incyte): First topical JAK for mild-to-moderate AD (U.S. 2021; updated labeling 2022).

    Market momentum

• • Dupilumab (Dupixent, Sanofi/Regeneron): ~$11.6B global sales in 2023; U.S. Dupixent market estimated at ~$10.4B in 2024.

Drivers

• Rising global prevalence (≈10–20% children; 2–10% adults), more diagnosis, and persistent disease burden.

• Biologic/JAK adoption for moderate-to-severe AD; multiple new mechanisms (IL-4/13, IL-13 only, IL-31r, JAK1).

• Pediatric & adolescent label expansions broadening treatable population.

• Patient demand for steroid-sparing options and itch control (pruritus-targeting).

Restraints

• Boxed warnings for oral JAK inhibitors (class safety communication: ↑ risk of MACE, malignancy, VTE, death) dampen uptake in some cohorts and add monitoring burden. 

• High biologic costs and payer step-therapy criteria limit access (especially outside U.S./EU). (Supported indirectly by slower APAC uptake vs. disease burden.) 

• Heterogeneous disease with variable long-term response; adherence issues with topicals. (General dermatology consensus; reflected in guideline and label usage constraints.)

Regional segmentation analysis

• North America: Largest revenue share today; high biologic/JAK penetration. (E.g., dermatitis drugs market NA share ~52% in 2024.) 

• Europe: Strong biologic uptake (dupilumab, tralokinumab; baricitinib EU-only for AD) with robust reimbursement frameworks. 

• Asia-Pacific: Fastest growth on rising diagnosis, access, and recent approvals; estimates suggest double-digit CAGR through 2033. 

Emerging Trends

• New pathways: IL-31 receptor blockade (nemolizumab) for itch-focused control; IL-13-only targeting (tralokinumab); high-affinity IL-13 (lebrikizumab).

• Topical JAKs as steroid-sparing options (ruxolitinib cream).

• Younger age approvals (down to 6 months for some biologics) expanding eligible pool.

• Rapid growth of flagship brands (Dupixent) setting therapeutic standard; biosimilar watch post-exclusivity.

Top Use Cases

• Mild–moderate AD: Emollients, TCS/TCI; add ruxolitinib cream for steroid-sparing or sensitive areas.

• Moderate–severe AD (systemic): Dupilumab first-line biologic; tralokinumab or lebrikizumab as IL-13 options; upadacitinib/abrocitinib (oral JAK1) for rapid control where appropriate. 

Major Challenges

• Safety/risk management and REMS-like vigilance for JAKs.

• Access & affordability (biologic pricing; prior auth/step edits).

• Long-term data needs for newer mechanisms (IL-31r, long-acting IL-13).

Attractive Opportunities

• APAC expansion via localization, patient-support programs, and payer partnerships (double-digit CAGR). 

• Pediatric & adolescent segments with high prevalence and unmet itch/sleep needs. 

• Differentiated positioning (e.g., itch-first claims with IL-31r; less frequent dosing with IL-13 biologics).

• Lifecycle & device innovation (autoinjectors, home administration) to improve adherence.

Key Factors of Market Expansion

• Epidemiology tailwinds: >200M people globally with AD across ages; prevalence rising over decades.

• Therapeutic innovation: Multiple new MOAs and topical/systemic options broadening choices.

• Guideline & label evolution: Younger ages, combination with topicals, maintenance strategies.

• Commercial durability of anchors: Dupixent growth and delayed biosimilar entry (U.S. key patents often cited out to ~2031).

Company reference list (who’s shaping the market)

• Sanofi / Regeneron – Dupixent (IL-4/13). 2023 global sales ≈ $11.6B; dominates biologic AD share.

• AbbVie – Rinvoq (upadacitinib, oral JAK1) for moderate-to-severe AD; patents suggest long runway (U.S. generic ~2036).

• Pfizer – Cibinqo (abrocitinib, oral JAK1) for moderate-to-severe AD.

• LEO Pharma – Tralokinumab (Adbry/Adtralza, IL-13) approved U.S./EU.

• Eli Lilly – Lebrikizumab (Ebglyss, IL-13) U.S./EU approvals (2024).

• Incyte – Opzelura (ruxolitinib 1.5% cream), first topical JAK for AD.

• Galderma – Nemluvio (nemolizumab, IL-31r) FDA-approved for AD (Dec 2024) and PN.

Market sizing (for context)

Recent published estimates vary by scope/methodology, but all point to robust growth:

• $10–13B in 2024–2025, expanding to $22–32B by early-to-mid 2030s (CAGR ~7–13%).

If you want this formatted into a one-pager or slide with logos and a compact TAM/SAM/SOM view, say the word—I’ll package it cleanly.